A new study suggests that pretreatment with cyclophosphamide can enhance treatment benefit in otherwise refractory patients with myasthenia gravis. Eight patients with myasthenia gravis that was unresponsive to standard therapy received intravenous cyclophosphamide for 6 weeks. Six of the eight patients responded well to standard immunotherapies after cyclophosphamide induction, and four of them remained in remission for over 2 years.
References
Buzzard, K. A. et al. Induction IV cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve 10.1002/mus.24536
Rights and permissions
About this article
Cite this article
Patients with refractory myasthenia gravis respond to immunotherapy after cyclophosphamide induction. Nat Rev Neurol 11, 4 (2015). https://doi.org/10.1038/nrneurol.2014.247
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2014.247